SELLAS Life Sciences Group, Inc. (SLS)
$2.2
Rating:
Recommendation:
Buy
| Symbol | SLS |
|---|---|
| Price | $2.2 |
| Beta | 1.805 |
| Volume Avg. | 0.23M |
| Market Cap | 45.178M |
| Shares () | - |
| 52 Week Range | 2.1-10.82 |
| 1y Target Est | - |
| DCF Unlevered | SLS DCF -> | |
|---|---|---|
| DCF Levered | SLS LDCF -> | |
| ROE | -166.08% | Strong Sell |
| ROA | -163.48% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 432.52% | Strong Buy |
| P/E | - | |
| P/B | 8.69 | Strong Buy |
Latest SLS news
About
Download (Excel)SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.